SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Financing Cash Flow
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Financing Cash Flow of $8.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $5.00M, a 36.62% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $3.21M, a 37.31% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.27M, a 49.05% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$96.38K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $10.95M, a 191.66% increase from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $3.76M, a 46.11% increase from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $2.57M, a 75.71% decline from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $10.58M, a 1437.78% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | $8.21M 10-Q · filed 2026-09-24 | $10.48M derived: sum of 3 quarters · filed 2026-09-24 | $10.38M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2026-03-31 | $3.21M 10-Q · filed 2026-05-15 | $5.48M derived: sum of 2 quarters · filed 2026-05-15 | $5.38M derived: sum of 3 quarters · filed 2026-05-15 | $9.04M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.17M derived: sum of 2 quarters · filed 2026-03-31 | $5.83M derived: sum of 3 quarters · filed 2026-09-24 | $10.95M 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$96.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.56M derived: sum of 2 quarters · filed 2026-09-24 | $8.68M 10-Q · filed 2025-11-13 | $13.14M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-06-30 | $3.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | $8.78M 10-Q · filed 2026-09-24 | $13.23M derived: sum of 3 quarters · filed 2026-09-24 | $13.04M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-03-31 | $5.12M 10-Q · filed 2026-05-15 | $9.57M derived: sum of 2 quarters · filed 2026-05-15 | $9.38M derived: sum of 3 quarters · filed 2026-05-15 | $8.91M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $4.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.26M derived: sum of 2 quarters · filed 2026-03-31 | $3.80M derived: sum of 3 quarters · filed 2026-03-31 | $3.76M 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$196.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$658.46K derived: sum of 2 quarters · filed 2025-11-13 | -$698.46K 10-Q · filed 2025-11-13 | -$1.03M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$461.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$501.67K 10-Q · filed 2025-08-13 | -$836.11K derived: sum of 3 quarters · filed 2025-08-13 | -$836.11K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$40.00K 10-Q · filed 2025-05-08 | -$374.44K derived: sum of 2 quarters · filed 2025-05-08 | -$374.44K derived: sum of 3 quarters · filed 2025-05-08 | -$513.67K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$334.44K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$334.44K derived: sum of 2 quarters · filed 2025-02-26 | -$473.67K derived: sum of 3 quarters · filed 2025-02-26 | $2.57M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$139.23K derived: sum of 2 quarters · filed 2024-11-13 | $2.90M 10-Q · filed 2024-11-13 | $2.84M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$139.23K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-09-04 | $2.90M 10-Q · filed 2024-09-04 | $2.84M derived: sum of 3 quarters · filed 2024-09-04 | $12.96M derived: sum of 4 quarters · filed 2024-09-04 | |
| 2023-03-31 | $3.04M 10-Q/A · filed 2024-09-04 | $2.98M derived: sum of 2 quarters · filed 2024-09-04 | $13.10M derived: sum of 3 quarters · filed 2024-09-04 | $13.10M derived: sum of 4 quarters · filed 2024-09-04 | |
| 2022-12-31 | -$67.36K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | $10.05M derived: sum of 2 quarters · filed 2024-09-04 | $10.05M derived: sum of 3 quarters · filed 2024-09-04 | $10.58M 10-K/A · filed 2024-09-04 | $10.62M 10-K · filed 2023-03-15 |
| 2022-09-30 | $10.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $10.12M derived: sum of 2 quarters · filed 2023-11-13 | $10.65M 10-Q · filed 2023-11-13 | $11.14M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $525.72K 10-Q · filed 2023-08-14 | $1.02M derived: sum of 3 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $525.72K 10-Q · filed 2023-05-25 | $1.02M derived: sum of 2 quarters · filed 2023-05-25 | |||
| 2021-12-31 | $494.93K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $687.93K 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $193.01K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |